The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994

doi:10.1056/NEJM199908193410802

Volume 341:556-562		August 19, 1999		Number 8

The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994

Miriam J. Alter, Ph.D., Deanna Kruszon-Moran, M.S., Omana V. Nainan, Ph.D., Geraldine M. McQuillan, Ph.D., Fengxiang Gao, M.D., Linda A. Moyer, B.S., Richard A. Kaslow, M.D., M.P.H., and Harold S. Margolis, M.D.

Full Text

PDF

Letters

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

ABSTRACT

Background Because many persons with chronic hepatitis C virus(HCV) infection are asymptomatic, population-based serologicstudies are needed to estimate the prevalence of the infectionand to develop and evaluate prevention efforts.

Methods We performed tests for antibody to HCV (anti-HCV) onserum samples from 21,241 persons six years old or older whoparticipated in the third National Health and Nutrition ExaminationSurvey, conducted during 1988 through 1994. We determined theprevalence of HCV RNA by means of nucleic acid amplificationand the genotype by means of sequencing.

Results The overall prevalence of anti-HCV was 1.8 percent,corresponding to an estimated 3.9 million persons nationwide(95 percent confidence interval, 3.1 million to 4.8 million)with HCV infection. Sixty-five percent of the persons with HCVinfection were 30 to 49 years old. Seventy-four percent werepositive for HCV RNA, indicating that an estimated 2.7 millionpersons in the United States (95 percent confidence interval,2.4 million to 3.0 million) were chronically infected, of whom73.7 percent were infected with genotype 1 (56.7 percent withgenotype 1a, and 17.0 percent with genotype 1b). Among subjects17 to 59 years of age, the strongest factors independently associatedwith HCV infection were illegal drug use and high-risk sexualbehavior. Other factors independently associated with infectionincluded poverty, having had 12 or fewer years of education,and having been divorced or separated. Neither sex nor racial–ethnicgroup was independently associated with HCV infection.

Conclusions In the United States, about 2.7 million personsare chronically infected with HCV. People who use illegal drugsor engage in high-risk sexual behavior account for most personswith HCV infection.

Source Information

From the Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta (M.J.A., O.V.N., F.G., L.A.M., H.S.M.); the National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Md. (D.K.-M., G.M.M.); and the National Institute of Allergy and Infectious Diseases, Bethesda, Md. (R.A.K.).

Address reprint requests to Dr. Alter at the Hepatitis Branch, Mailstop G37, Centers for Disease Control and Prevention, Atlanta, GA 30333.

Full Text of this Article

Related Letters:

Prevalence of Hepatitis C Virus Infection in the United States
Murphy E. L., Bryzman S., Williams A. E., Dore G. J., Law M. G., Kaldor J. M., Stroffolini T., D'Argenio P., Mele A., Alter M. J., Kruszon-Moran D., McQuillan G. M.
Extract | Full Text
N Engl J Med 1999; 341:2093-2095, Dec 30, 1999. Correspondence

This article has been cited by other articles:

King, L. A., Le Strat, Y., Meffre, C., Delarocque-Astagneau, E., Desenclos, J.-C. (2009). Assessment and proposal of a new combination of screening criteria for hepatitis C in France. Eur J Public Health 19: 527-533 [Abstract] [Full Text]
De Angelis, D., Sweeting, M., Ades, A., Hickman, M., Hope, V., Ramsay, M. (2009). An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales. Stat Methods Med Res 18: 361-379 [Abstract]
Kiser, J. J. (2009). Trends in the Treatment of Chronic Hepatitis C Virus Infection. Journal of Pharmacy Practice 22: 405-418 [Abstract]
Taouli, B., Ehman, R. L., Reeder, S. B. (2009). Advanced MRI Methods for Assessment of Chronic Liver Disease. Am. J. Roentgenol. 193: 14-27 [Abstract] [Full Text]
RAMOS-CASALS, M., MUNOZ, S., MEDINA, F., JARA, L.-J., ROSAS, J., CALVO-ALEN, J., BRITO-ZERON, P., FORNS, X., SANCHEZ-TAPIAS, J.-M., for the HISPAMEC Study Group, (2009). Systemic Autoimmune Diseases in Patients with Hepatitis C Virus Infection: Characterization of 1020 Cases (The HISPAMEC Registry). The Journal of Rheumatology 36: 1442-1448 [Abstract] [Full Text]
Silberbogen, A. K., Ulloa, E. W., Janke, E. A., Mori, D. L. (2009). Psychosocial Issues and Mental Health Treatment Recommendations for Patients With Hepatitis C. Psychosomatics 50: 114-122 [Abstract] [Full Text]
Chiao, E. Y., Engels, E. A., Kramer, J. R., Pietz, K., Henderson, L., Giordano, T. P., Landgren, O. (2009). Risk of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia Among 120 908 US Veterans With Hepatitis C Virus Infection. Arch Intern Med 169: 357-363 [Abstract] [Full Text]
Yee, L. J., Im, K., Wahed, A. S., Bugawan, T., Li, J., Rhodes, S. L., Erlich, H., Rosen, H. R., Liang, T. J., Yang, H., for the Virahep-C Study, (2009). Polymorphism in the Human Major Histocompatibility Complex and Early Viral Decline during Treatment of Chronic Hepatitis C. Antimicrob. Agents Chemother. 53: 615-621 [Abstract] [Full Text]
Rodriguez-Torres, M., Jeffers, L. J., Sheikh, M. Y., Rossaro, L., Ankoma-Sey, V., Hamzeh, F. M., Martin, P., the Latino Study Group, (2009). Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C. NEJM 360: 257-267 [Abstract] [Full Text]
Himelhoch, S., McCarthy, J. F., Ganoczy, D., Medoff, D., Kilbourne, A., Goldberg, R., Dixon, L., Blow, F. C. (2009). Understanding Associations Between Serious Mental Illness and Hepatitis C Virus Among Veterans: A National Multivariate Analysis. Psychosomatics 50: 30-37 [Abstract] [Full Text]
Gwynn, R. C., Garg, R. K., Kerker, B. D., Frieden, T. R., Thorpe, L. E. (2009). Contributions of a Local Health Examination Survey to the Surveillance of Chronic and Infectious Diseases in New York City. AJPH 99: 152-159 [Abstract] [Full Text]
Rutebemberwa, A., Ray, S. C., Astemborski, J., Levine, J., Liu, L., Dowd, K. A., Clute, S., Wang, C., Korman, A., Sette, A., Sidney, J., Pardoll, D. M., Cox, A. L. (2008). High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection. J. Immunol. 181: 8215-8225 [Abstract] [Full Text]
Janke, E. A., McGraw, S., Garcia-Tsao, G., Fraenkel, L. (2008). Psychosocial Issues in Hepatitis C: A Qualitative Analysis. Psychosomatics 49: 494-501 [Abstract] [Full Text]
Daniel, H. D. J., David, J., Grant, P. R., Garson, J. A., Chandy, G. M., Abraham, P. (2008). Whole Blood as an Alternative to Plasma for Detection of Hepatitis C Virus RNA. J. Clin. Microbiol. 46: 3791-3794 [Abstract] [Full Text]
Black, M., Thomas, R. (2008). Antiviral Treatment for Hepatitis C Cirrhosis: Is the Effort Justified?. ANN INTERN MED 149: 427-428 [Full Text]
Li, H., Thomassen, L. V., Majid, A., McMahon, B. J., Bruden, D., McArdle, S., Bano, N., Chung, M., Carithers, R. L., Perkins, J. D., Sullivan, D. G., Gretch, D. R. (2008). Investigation of Putative Multisubtype Hepatitis C Virus Infections In Vivo by Heteroduplex Mobility Analysis of Core/Envelope Subgenomes. J. Virol. 82: 7524-7532 [Abstract] [Full Text]
Csete, M. (2008). Gender Issues in Transplantation. Anesth. Analg. 107: 232-238 [Abstract] [Full Text]
Dieperink, E., Leskela, J., Dieperink, M. E., Evans, B., Thuras, P., Ho, S. B. (2008). The Effect of Pegylated Interferon-{alpha}2b and Ribavirin on Posttraumatic Stress Disorder Symptoms. Psychosomatics 49: 225-229 [Abstract] [Full Text]
Rousseau, C. M., Ioannou, G. N., Todd-Stenberg, J. A., Sloan, K. L., Larson, M. F., Forsberg, C. W., Dominitz, J. A. (2008). Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort Study. AJPH 98: 846-852 [Abstract] [Full Text]
Murakami, E., Niu, C., Bao, H., Micolochick Steuer, H. M., Whitaker, T., Nachman, T., Sofia, M. A., Wang, P., Otto, M. J., Furman, P. A. (2008). The Mechanism of Action of {beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to {beta}-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob. Agents Chemother. 52: 458-464 [Abstract] [Full Text]
Zhang, Y., Weady, P., Duggal, R., Hao, W. (2008). Novel Chimeric Genotype 1b/2a Hepatitis C Virus Suitable for High-Throughput Screening. Antimicrob. Agents Chemother. 52: 666-674 [Abstract] [Full Text]
Hser, Y.-I., Huang, D., Chou, C.-P., Anglin, M. D. (2007). Trajectories of Heroin Addiction: Growth Mixture Modeling Results Based on a 33-Year Follow-Up Study. Eval Rev 31: 548-563 [Abstract]
Tang, W., Lazaro, C. A., Campbell, J. S., Parks, W. T., Katze, M. G., Fausto, N. (2007). Responses of Nontransformed Human Hepatocytes to Conditional Expression of Full-Length Hepatitis C Virus Open Reading Frame. Am. J. Pathol. 171: 1831-1846 [Abstract] [Full Text]
Ma, H., Jiang, W.-R., Robledo, N., Leveque, V., Ali, S., Lara-Jaime, T., Masjedizadeh, M., Smith, D. B., Cammack, N., Klumpp, K., Symons, J. (2007). Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5'-Triphosphate Species. J. Biol. Chem. 282: 29812-29820 [Abstract] [Full Text]
Freudenreich, O., Gandhi, R. T., Walsh, J. P., Henderson, D. C., Goff, D. C. (2007). Hepatitis C in Schizophrenia: Screening Experience in a Community-Dwelling Clozapine Cohort. Psychosomatics 48: 405-411 [Abstract] [Full Text]
Goedert, J. J., Chen, B. E., Preiss, L., Aledort, L. M., Rosenberg, P. S., for the Second Multicenter Hemophilia Cohort Study, (2007). Reconstruction of the Hepatitis C Virus Epidemic in the US Hemophilia Population, 1940-1990. Am J Epidemiol 165: 1443-1453 [Abstract] [Full Text]
Radziewicz, H., Ibegbu, C. C., Fernandez, M. L., Workowski, K. A., Obideen, K., Wehbi, M., Hanson, H. L., Steinberg, J. P., Masopust, D., Wherry, E. J., Altman, J. D., Rouse, B. T., Freeman, G. J., Ahmed, R., Grakoui, A. (2007). Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression. J. Virol. 81: 2545-2553 [Abstract] [Full Text]
Butt, A. A, Justice, A. C, Skanderson, M., Rigsby, M. O, Good, C. B, Kwoh, C K. (2007). Rate and predictors of treatment prescription for hepatitis C. Gut 56: 385-389 [Abstract] [Full Text]
Cagle, H. H, Jacob, J., Homan, C. E., Williams, J. L., Christensen, C. J., McMahon, B. J. (2007). Results of a General Hepatitis C Lookback Program for Persons Who Received Blood Transfusions in a Neonatal Intensive Care Unit Between January 1975 and July 1992. Arch Pediatr Adolesc Med 161: 125-130 [Abstract] [Full Text]
Armstrong, G. L. (2007). Injection Drug Users in the United States, 1979-2002: An Aging Population. Arch Intern Med 167: 166-173 [Abstract] [Full Text]
Marotte, H., Fontanges, E., Bailly, F., Zoulim, F., Trepo, C., Miossec, P. (2007). Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 46: 97-99 [Abstract] [Full Text]
Ghosn, J, Deveau, C, Goujard, C, Garrigue, I, Saichi, N, Galimand, J, Nagy, Z, Rouzioux, C, Meyer, L, Chaix, M-L, for the French PRIMO Cohort Study Group (ANRS CO 0, (2006). Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex. Transm. Infect. 82: 458-460 [Abstract] [Full Text]
Patel, P. R., Larson, A. K., Castel, A. D., Ganova-Raeva, L. M., Myers, R. A., Roup, B. J., Farrell, K. P., Edwards, L., Nainan, O., Krick, J. P., Blythe, D., Fiore, A. E., Roche, J. C. (2006). Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies.. JAMA 296: 2005-2011 [Abstract] [Full Text]
Lincoln, T., Tuthill, R. W., DePietro, S. L., Tocco, M. J., Keough, K., Conklin, T. J. (2006). Viral Hepatitis, Risk Behaviors, Aminotransferase Levels, and Screening Options at a County Correctional Center. J Correct Health Care 12: 249-261 [Abstract]
Grieve, R, Roberts, J, Wright, M, Sweeting, M, DeAngelis, D, Rosenberg, W, Bassendine, M, Main, J, Thomas, H (2006). Cost effectiveness of interferon {alpha} or peginterferon {alpha} with ribavirin for histologically mild chronic hepatitis C. Gut 55: 1332-1338 [Abstract] [Full Text]
Buckton, A. J., Ngui, S.-L., Arnold, C., Boast, K., Kovacs, J., Klapper, P. E., Patel, B., Ibrahim, I., Rangarajan, S., Ramsay, M. E., Teo, C.-G. (2006). Multitypic hepatitis C virus infection identified by real-time nucleotide sequencing of minority genotypes.. J. Clin. Microbiol. 44: 2779-2784 [Abstract] [Full Text]
Matthews, A. M., Fireman, M., Zucker, B., Sobel, M., Hauser, P. (2006). Relapse to Opioid Use After Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin. Am. J. Psychiatry 163: 1342-1347 [Full Text]
Bakr, I, Rekacewicz, C, El Hosseiny, M, Ismail, S, El Daly, M, El-Kafrawy, S, Esmat, G, Hamid, M A, Mohamed, M K, Fontanet, A (2006). Higher clearance of hepatitis C virus infection in females compared with males. Gut 55: 1183-1187 [Abstract] [Full Text]
Crone, C. C., Gabriel, G. M., DiMartini, A. (2006). An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist. Psychosomatics 47: 188-205 [Abstract] [Full Text]
Bracho, M. A., Carrillo-Cruz, F. Y., Ortega, E., Moya, A., Gonzalez-Candelas, F. (2006). A new subtype of hepatitis C virus genotype 1: complete genome and phylogenetic relationships of an Equatorial Guinea isolate. J. Gen. Virol. 87: 1697-1702 [Abstract] [Full Text]
McGlynn, K. A., Tarone, R. E., El-Serag, H. B. (2006). A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States.. Cancer Epidemiol. Biomarkers Prev. 15: 1198-1203 [Abstract] [Full Text]
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., Alter, M. J. (2006). The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. ANN INTERN MED 144: 705-714 [Abstract] [Full Text]
Dienstag, J. L. (2006). Hepatitis C: A Bitter Harvest. ANN INTERN MED 144: 770-771 [Full Text]
Lecube, A., Hernandez, C., Genesca, J., Simo, R. (2006). Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis. Diabetes Care 29: 1140-1149 [Full Text]
Lee, V. S. (2006). Science to Practice: Can MR Imaging Replace Liver Biopsy for the Diagnosis of Early Fibrosis?. Radiology 239: 309-310 [Abstract] [Full Text]
Tsui, J. I., Vittinghoff, E., Shlipak, M. G., O'Hare, A. M. (2006). Relationship between Hepatitis C and Chronic Kidney Disease: Results from the Third National Health and Nutrition Examination Survey. J. Am. Soc. Nephrol. 17: 1168-1174 [Abstract] [Full Text]
Navarro, V. J., Senior, J. R. (2006). Drug-Related Hepatotoxicity. NEJM 354: 731-739 [Full Text]
Zhang, M., Rosenberg, P. S., Brown, D. L., Preiss, L., Konkle, B. A., Eyster, M. E., Goedert, J. J., for the Second Multicenter Hemophilia Cohort Study, (2006). Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 107: 892-897 [Abstract] [Full Text]
Nainan, O. V., Lu, L., Gao, F.-X., Meeks, E., Robertson, B. H., Margolis, H. S. (2006). Selective transmission of hepatitis C virus genotypes and quasispecies in humans and experimentally infected chimpanzees. J. Gen. Virol. 87: 83-91 [Abstract] [Full Text]
Hazari, S., Patil, A., Joshi, V., Sullivan, D. E., Fermin, C. D., Garry, R. F., Elliott, R. M., Dash, S. (2005). Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes. J. Gen. Virol. 86: 3047-3053 [Abstract] [Full Text]
Tugwell, B. D., Patel, P. R., Williams, I. T., Hedberg, K., Chai, F., Nainan, O. V., Thomas, A. R., Woll, J. E., Bell, B. P., Cieslak, P. R. (2005). Transmission of Hepatitis C Virus to Several Organ and Tissue Recipients from an Antibody-Negative Donor. ANN INTERN MED 143: 648-654 [Abstract] [Full Text]
Geppert, C. M.A., Dettmer, E., Jakiche, A. (2005). Ethical Challenges in the Care of Persons With Hepatitis C Infection: A Pilot Study to Enhance Informed Consent With Veterans. Psychosomatics 46: 392-401 [Abstract] [Full Text]
Rodriguez-Torres, M., Torriani, F. J., Soriano, V., Borucki, M. J., Lissen, E., Sulkowski, M., Dieterich, D., Wang, K., Gries, J.-M., Hoggard, P. G., Back, D., for the APRICOT Study Group, (2005). Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. Antimicrob. Agents Chemother. 49: 3997-4008 [Abstract] [Full Text]
Gemignani, F, Brindani, F, Alfieri, S, Giuberti, T, Allegri, I, Ferrari, C, Marbini, A (2005). Clinical spectrum of cryoglobulinaemic neuropathy. J. Neurol. Neurosurg. Psychiatry 76: 1410-1414 [Abstract] [Full Text]
Anand, B S, Thornby, J (2005). Alcohol has no effect on hepatitis C virus replication: a meta-analysis. Gut 54: 1468-1472 [Abstract] [Full Text]
Nguyen, M. T., Herrine, S. K., Laine, C. A., Ruth, K., Weinberg, D. S. (2005). Description of a New Hepatitis C Risk Assessment Tool. Arch Intern Med 165: 2013-2018 [Abstract] [Full Text]
Munoz-Plaza, C. E., Strauss, S. M., Astone, J. M., Des Jarlais, D. C., Hagan, H. (2005). Hepatitis C Service Delivery in Prisons: Peer Education From the "Guys in Blue". J Correct Health Care 11: 347-368 [Abstract]
Macedo de Oliveira, A., White, K. L., Leschinsky, D. P., Beecham, B. D., Vogt, T. M., Moolenaar, R. L., Perz, J. F., Safranek, T. J. (2005). An Outbreak of Hepatitis C Virus Infections among Outpatients at a Hematology/Oncology Clinic. ANN INTERN MED 142: 898-902 [Abstract] [Full Text]
Perez, C. M, Suarez, E., Torres, E. A, Roman, K., Colon, V. (2005). Seroprevalence of hepatitis C virus and associated risk behaviours: a population-based study in San Juan, Puerto Rico. Int J Epidemiol 34: 593-599 [Abstract] [Full Text]
Lo Re, V III, Kostman, J R (2005). Management of chronic hepatitis C. Postgrad. Med. J. 81: 376-382 [Abstract] [Full Text]
Rifai, M. A., Rosenstein, D. L. (2005). Hepatitis C and Psychiatry. Focus 3: 194-202 [Abstract] [Full Text]
Chambers, T. J., Fan, X., Droll, D. A., Hembrador, E., Slater, T., Nickells, M. W., Dustin, L. B., DiBisceglie, A. M. (2005). Quasispecies Heterogeneity within the E1/E2 Region as a Pretreatment Variable during Pegylated Interferon Therapy of Chronic Hepatitis C Virus Infection. J. Virol. 79: 3071-3083 [Abstract] [Full Text]
Matsumori, A. (2005). Hepatitis C Virus Infection and Cardiomyopathies. Circ. Res. 96: 144-147 [Full Text]
Germer, J. J., Harmsen, W. S., Mandrekar, J. N., Mitchell, P. S., Yao, J. D. C. (2005). Evaluation of the COBAS TaqMan HCV Test with Automated Sample Processing Using the MagNA Pure LC Instrument. J. Clin. Microbiol. 43: 293-298 [Abstract] [Full Text]
Abdallah, M. A., Hull, C., Horn, T. D. (2005). Necrolytic Acral Erythema: A Patient From the United States Successfully Treated With Oral Zinc. Arch Dermatol 141: 85-87 [Abstract] [Full Text]
Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Goujard, C., Pialoux, G., Piroth, L., Salmon-Ceron, D., Degott, C., Cacoub, P., Perronne, C., for the ANRS HCO2 RIBAVIC Study Team, (2004). Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients: A Randomized Controlled Trial. JAMA 292: 2839-2848 [Abstract] [Full Text]
Mas, A., Ulloa, E., Bruguera, M., Furcic, I., Garriga, D., Fabregas, S., Andreu, D., Saiz, J. C., Diez, J. (2004). Hepatitis C virus population analysis of a single-source nosocomial outbreak reveals an inverse correlation between viral load and quasispecies complexity. J. Gen. Virol. 85: 3619-3626 [Abstract] [Full Text]
Meyer, K., Beyene, A., Bowlin, T. L., Basu, A., Ray, R. (2004). Coexpression of Hepatitis C Virus E1 and E2 Chimeric Envelope Glycoproteins Displays Separable Ligand Sensitivity and Increases Pseudotype Infectious Titer. J. Virol. 78: 12838-12847 [Abstract] [Full Text]
ONYIKE, C. U., BONNER, J. O., LYKETSOS, C. G., TREISMAN, G. J. (2004). Dr. Onyike and Colleagues Reply. Am. J. Psychiatry 161: 2332-2334 [Full Text]
Li, Y., Zhang, T., Ho, C., Orange, J. S., Douglas, S. D., Ho, W.-Z. (2004). Natural killer cells inhibit hepatitis C virus expression. J. Leukoc. Biol. 76: 1171-1179 [Abstract] [Full Text]
Bini, E. J., Mehandru, S. (2004). Incidence of Thyroid Dysfunction During Interferon Alfa-2b and Ribavirin Therapy in Men With Chronic Hepatitis C: A Prospective Cohort Study. Arch Intern Med 164: 2371-2376 [Abstract] [Full Text]
McQuillan, G. M., Kruszon-Moran, D., Kottiri, B. J., Curtin, L. R., Lucas, J. W., Kington, R. S. (2004). Racial and Ethnic Differences in the Seroprevalence of 6 Infectious Diseases in the United States: Data From NHANES III, 1988-1994. AJPH 94: 1952-1958 [Abstract] [Full Text]
Calabrese, L H, Zein, N, Vassilopoulos, D (2004). Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63: ii18-ii24 [Abstract] [Full Text]
Einav, S., Elazar, M., Danieli, T., Glenn, J. S. (2004). A Nucleotide Binding Motif in Hepatitis C Virus (HCV) NS4B Mediates HCV RNA Replication. J. Virol. 78: 11288-11295 [Abstract] [Full Text]
Elazar, M., Liu, P., Rice, C. M., Glenn, J. S. (2004). An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication. J. Virol. 78: 11393-11400 [Abstract] [Full Text]
Schuval, S., Van Dyke, R. B., Lindsey, J. C., Palumbo, P., Mofenson, L. M., Oleske, J. M., Cervia, J., Kovacs, A., Dankner, W. N., Smith, E., Nowak, B., Ciupak, G., Webb, N., Eagle, M., Smith, D., Hennessey, R., Goodman-Kerkau, M., Levin, M. J., for the Pediatric AIDS Clinical Trials Group Proto, (2004). Hepatitis C Prevalence in Children With Perinatal Human Immunodeficiency Virus Infection Enrolled in a Long-term Follow-up Protocol. Arch Pediatr Adolesc Med 158: 1007-1013 [Abstract] [Full Text]
Salomon, J. A, Weinstein, M. C, Goldie, S. J (2004). Taking account of future technology in cost effectiveness analysis. BMJ 329: 733-736 [Full Text]
Krajden, M., Shivji, R., Gunadasa, K., Mak, A., McNabb, G., Friesenhahn, M., Hendricks, D., Comanor, L. (2004). Evaluation of the Core Antigen Assay as a Second-Line Supplemental Test for Diagnosis of Active Hepatitis C Virus Infection. J. Clin. Microbiol. 42: 4054-4059 [Abstract] [Full Text]
Cook, L., Ng, K.-W., Bagabag, A., Corey, L., Jerome, K. R. (2004). Use of the MagNA Pure LC Automated Nucleic Acid Extraction System followed by Real-Time Reverse Transcription-PCR for Ultrasensitive Quantitation of Hepatitis C Virus RNA. J. Clin. Microbiol. 42: 4130-4136 [Abstract] [Full Text]
Liu, Z., Netski, D. M., Mao, Q., Laeyendecker, O., Ticehurst, J. R., Wang, X.-H., Thomas, D. L., Ray, S. C. (2004). Accurate Representation of the Hepatitis C Virus Quasispecies in 5.2-Kilobase Amplicons. J. Clin. Microbiol. 42: 4223-4229 [Abstract] [Full Text]
Mendez-Sanchez, N., Motola-Kuba, D., Chavez-Tapia, N. C., Bahena, J., Correa-Rotter, R., Uribe, M. (2004). Prevalence of Hepatitis C Virus Infection among Hemodialysis Patients at a Tertiary-Care Hospital in Mexico City, Mexico. J. Clin. Microbiol. 42: 4321-4322 [Abstract] [Full Text]
Wilson, C. (2004). Hepatitis C Infection and Type 2 Diabetes in American-Indian Women. Diabetes Care 27: 2116-2119 [Abstract] [Full Text]
Zou, S., Dodd, R. Y., Stramer, S. L., Strong, D. M., the Tissue Safety Study Group, (2004). Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United States. NEJM 351: 751-759 [Abstract] [Full Text]
Carella, C., Mazziotti, G., Amato, G., Braverman, L. E., Roti, E. (2004). Interferon-{alpha}-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects. J. Clin. Endocrinol. Metab. 89: 3656-3661 [Full Text]
Matthews, J. D., Bini, E. J. (2004). Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C. Journal of Pharmacy Practice 17: 229-238 [Abstract]
Jakkula, M., Boucher, T. A., Beyendorff, U., Conn, S. M., Johnson, J. E., Nolan, C. J., Peine, C. J., Albrecht, J. H. (2004). A Randomized Trial of Chinese Herbal Medicines for the Treatment of Symptomatic Hepatitis C. Arch Intern Med 164: 1341-1346 [Abstract] [Full Text]
Muir, A. J., Bornstein, J. D., Killenberg, P. G., the Atlantic Coast Hepatitis Treatment Group, (2004). Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites. NEJM 350: 2265-2271 [Abstract] [Full Text]
Basu, A., Beyene, A., Meyer, K., Ray, R. (2004). The Hypervariable Region 1 of the E2 Glycoprotein of Hepatitis C Virus Binds to Glycosaminoglycans, but This Binding Does Not Lead to Infection in a Pseudotype System. J. Virol. 78: 4478-4486 [Abstract] [Full Text]
Dufour, D. R. (2004). Lot-to-Lot Variation in Anti-Hepatitis C Signal-to-Cutoff Ratio. Clin. Chem. 50: 958-960 [Full Text]
Netski, D. M., Wang, X.-H., Mehta, S. H., Nelson, K., Celentano, D., Thongsawat, S., Maneekarn, N., Suriyanon, V., Jittiwutikorn, J., Thomas, D. L., Ticehurst, J. R. (2004). Hepatitis C Virus (HCV) Core Antigen Assay To Detect Ongoing HCV Infection in Thai Injection Drug Users. J. Clin. Microbiol. 42: 1631-1636 [Abstract] [Full Text]
Hutchinson, S J, Goldberg, D J, King, M, Cameron, S O, Shaw, L E, Brown, A, MacKenzie, J, Wilson, K, MacDonald, L (2004). Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis. Gut 53: 593-598 [Abstract] [Full Text]
Chou, R., Clark, E. C., Helfand, M. (2004). Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED 140: 465-479 [Abstract] [Full Text]
Onyike, C. U., Bonner, J. O., Lyketsos, C. G., Treisman, G. J. (2004). Mania During Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin. Am. J. Psychiatry 161: 429-435 [Full Text]
Morton, L. M., Engels, E. A., Holford, T. R., Leaderer, B., Zhang, Y., Zahm, S. H., Boyle, P., Zhang, B., Flynn, S., Tallini, G., Owens, P. H., Zheng, T. (2004). Hepatitis C Virus and Risk of Non-Hodgkin Lymphoma: A Population-Based Case-Control Study among Connecticut Women. Cancer Epidemiol. Biomarkers Prev. 13: 425-430 [Abstract] [Full Text]
Adrain, A. L., Ramberan, H., Weaver, G. J. (2004). Evaluation of Common Liver Problems. J. Am. Podiatr. Med. Assoc. 94: 149-156 [Abstract] [Full Text]
Rocca, L. G., Yawn, B. P., Wollan, P., Kim, W. R. (2004). Management of Patients With Hepatitis C in a Community Population: Diagnosis, Discussions, and Decisions to Treat. Ann Fam Med 2: 116-124 [Abstract] [Full Text]
Stuyver, L. J., McBrayer, T. R., Whitaker, T., Tharnish, P. M., Ramesh, M., Lostia, S., Cartee, L., Shi, J., Hobbs, A., Schinazi, R. F., Watanabe, K. A., Otto, M. J. (2004). Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2'-Deoxy-2'-Fluorocytidine. Antimicrob. Agents Chemother. 48: 651-654 [Abstract] [Full Text]
Elbeik, T., Surtihadi, J., Destree, M., Gorlin, J., Holodniy, M., Jortani, S. A., Kuramoto, K., Ng, V., Valdes, R. Jr., Valsamakis, A., Terrault, N. A. (2004). Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA). J. Clin. Microbiol. 42: 563-569 [Abstract] [Full Text]

Comments and questions? Please contact us.